Diabetes is prevalent worldwide and represents an epidemic in the US:
T2DN is a kidney disease that affects individuals with diabetes. The number of individuals with diabetes is rising. The total number of adults 20 years of age or older with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The number of individuals with diabetes who develop diabetic kidney disease is estimated to be between 30 and 40%.
T2DN affects the kidney’s ability to function normally and is a large unmet medical disease. Diabetic nephropathy affects approximately 12 million US citizens and an estimated 170 million individuals worldwide. Approximately half of all chronic kidney disease and kidney failure has been attributed to diabetic complications. High levels of uric acid have been reported to be an independent risk factor in the progress of kidney disease in these patients, and is associated with increased blood pressure, systemic inflammation, cardiovascular injury, and endothelial dysfunction.
XORTX is developing XRx-225 as a treatment option for progressive kidney disease associated with elevated levels of uric acid.